

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 7 NOVEMBER 2022

Reference is made to the circular of Sinopharm Tech Holdings Limited (the “**Company**”) dated 21 October 2022 (the “**Circular**”) and the notice (the “**Notice**”) of the extraordinary general meeting of the Company (the “**EGM**”) dated 21 October 2022. Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Circular. All Directors attended the EGM in person or by electronic means.

POLL RESULTS OF THE EGM

The Board is pleased to announce that at the EGM held on Monday, 7 November 2022, the proposed ordinary resolution (the “**Resolution**”) as set out in the Notice was duly passed by the Independent Shareholders by way of poll.

The poll results in respect of the Resolution are as follows:

ORDINARY RESOLUTION*	Number of Votes (%)	
	For	Against
To approve, confirm and ratify the Loan Capitalisation Agreement and the transactions contemplated thereunder (including but not limited to the grant of the specific mandate to the Directors for the allotment and issue of the Loan Capitalisation Shares) and the grant of authorisation to the Directors in connection therewith	2,198,084,810 (100.00%)	0 (0.00%)

* Full text of the Resolution is set out in the Notice.

As more than 50% of the votes were cast in favour of the above Resolution, this Resolution was duly passed as ordinary resolution of the Company at the EGM.

Tricor Standard Limited, the Hong Kong Branch Share Registrar and Transfer Office of the Company, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

As at the date of the EGM, the total issued Share capital of the Company were 4,537,688,780 Shares. The Subscriber and his respective associates as illustrated in the table below were required to abstain and had abstained from voting on the Resolution at the EGM regarding the Loan Capitalisation Agreement and the transactions contemplated thereunder:

Name	Number of Shares directly held	Approximate Percentage of shareholding
The Subscriber	—	—
Madam CHEUNG Kwai Lan (a former Director resigned on 1 August 2022 and the mother of the Subscriber)	4,656,000	0.10%
Mr. CHAN Tung Mei (the father of the Subscriber)	3,020,000	0.07%
Ms. WOO Theresa (the spouse of the Subscriber)	—	—
Ms. CHAN Siu Sarah (the sister of the Subscriber)	—	—

Save as disclosed herein and to the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, no other Shareholder was required under the GEM Listing Rules to abstain from voting at the EGM. Accordingly, there were 4,530,012,780 Shares entitling the Independent Shareholders to attend and vote on the Resolution at the EGM. There were no Independent Shareholders who were entitled to attend the EGM but were only entitled to vote against the Resolution at the EGM.

By Order of the Board
Sinopharm Tech Holdings Limited
 國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 7 November 2022

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. LAM Kit Sun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.